(R)-IDO/TDO-IN-1 is an indoleamine 2,3-dioxygenase (IDO) inhibitor with favorable pharmacokinetic properties; it exhibits antitumor activity in the MC38 xenograft model and demonstrates synergistic effects with the anti-PD-1 monoclonal antibody (SHR-1210).